ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Mid Cap Strategy”. A copy of the letter can be downloaded here. Mid-cap stocks showed strong performance in Q1, with the Russell Midcap Index rising 1.3%, outperforming both large-cap and small-cap stocks. In contrast, large-cap equities dropped 4.2%, while small-caps increased by only 0.9%; this dynamic suggested broadening in market leadership. Though investor concerns about the US-Israel-Iran conflict influenced mid-cap stocks, their performance was more focused on company fundamentals and sector trends. However, the ClearBridge Mid Cap Strategy underperformed its benchmark due to challenges in the IT, health care, and consumer discretionary sectors. The Strategy focuses on the consumer discretionary sector, acquiring firms that can perform in a variety of circumstances while being adaptable as the environment changes. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, ClearBridge Mid Cap Strategy highlighted stocks like ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On April 10, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $106.81 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 9.43%, and its shares lost 27.21% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $8.31 billion.
ClearBridge Mid Cap Strategy stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
“Health care was an area of weakness during the quarter. Declines were particularly prevalent in contract research organization ICON Public Limited Company (NASDAQ:ICLR) and digital health platform Doximity, due to investor concerns over the possibility of AI disruption in drug development and advertising. We exited our ICON position during the quarter but continue to hold a small position in Doximity as we believe that it is competitively well positioned and, despite being caught up in near-term disruption concerns, will be a long-term beneficiary of AI.”
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 41 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the fourth quarter, up from 43 in the previous quarter. While we acknowledge the risk and potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ICON Public Limited Company (NASDAQ:ICLR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered ICON Public Limited Company (NASDAQ:ICLR) and shared Polen Global Growth Strategy’s views on the company in Q4 2025. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
